Growth in 340B covered entities’ use of contract pharmacies to dispense 340B drugs, coupled with growth in pharmacy benefit managers’ control over these pharmacies, has given PBMs an outsized, profit-driven role in the 340B program that does not benefit patients,
…
Six U.S. House members—three Democrats and three Republicans—are urging fellow representatives to sign a letter asking U.S. Health and Human Services (HHS) Department leaders “to begin enforcement actions against pharmaceutical companies that refuse to honor 340B discounts on prescription drugs.”
…
The National Association of Community Health Centers this week strongly urged drug manufacturer Merck to eliminate “all conditions imposed on health centers to receive 340B price drugs at contract pharmacies.”
Merck’s April 28 decision to extend its restrictions on 340B pricing
…
Drug manufacturers Novartis and United Therapeutics (UT) last night urged a federal appeals court in Washington, D.C., to affirm a lower court’s November 2021 judgement that the 340B statute does not stop manufacturers from attaching any conditions to 340B drug
…
Biopharmaceutical manufacturer Exelixis yesterday became the 17th drug maker to impose conditions on 340B pricing when hospitals use contract pharmacies.
The company, a specialty manufacturer with two high-priced drug products on the market, announced its policy in email notices to covered
…
Drug manufacturers AstraZeneca and Sanofi have asked a 340B administrative dispute resolution panel to dismiss the National Association of Community Health Centers’ claims that its members are being overcharged due to the companies’ denied or restricted 340B sales when health
…
Generic drug maker e5 Pharma is giving 340B covered entities refunds for overcharges on six NDCs of the barbiturate phenobarbital during Q1 2021, according to a public notice on the U.S. Health Resources and Services Administration (HRSA) website.
Florida-based e5
…
Pharmacy care services company OptumRx is requiring 340B covered entities to get its consent before they share OptumRx contract pharmacy claims data with drug manufacturers to satisfy manufacturers’ conditions on 340B pricing.
OptumRx—a part of information and health services business
…
Many 340B hospitals “may not offer low-income patients financial assistance to access medicines and may use extraordinary collection actions, including but not limited to, liens, foreclosures, and civil actions when patients fail to pay bills,” a pharmaceutical-industry funded study released
…*Sign up for news summaries and alerts from 340B Report